Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +17.92%
#2 Palladium Network Palladium Network +8.47%
#3 Cryptopia Cryptopia +4.23%
#4 Victoria VR Victoria VR +4.09%
#5 Lisk Lisk +3.02%
#6 Test Test +2.89%
#7 GRVT Token GRVT Token +2.39%
#8 Biconomy Biconomy +2.25%
#9 COTI COTI +2.22%
#10 Bless Bless +2.18%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Settings
Language
ENGLISH
Currency
USD
Theme
SK3 Group, Inc. SK3 Group, Inc.

SK3 Group, Inc.

SKTO
Rank in Stocks #42239
SK3 Group, Inc. offers strategic consulting, product authorization, and... SK3 Group, Inc. offers strategic consulting, product authorization, and promotional assistance to medical cannabis organizations situated in California. The company also grants licenses for the commercialization and distribution of a varied range of products. These include the YAK brand of medical marijuana edibles; Canna-Loz, an ingestion method for significant quantities of phyto-cannabinoids; Yeti, a pre-rolled item crafted for pain management; and Dharmanol, an exclusive technological process that isolates, stabilizes, and safeguards the beneficial cannabinoids from hemp and marijuana in their non-intoxicating form. Previously operating as CTT International Distributors, Inc., the company officially rebranded as SK3 Group, Inc. in May 2007. Founded in 2000, its main corporate base is located in Los Angeles, California. SK3 Group, Inc. is an affiliate of Healthcare of Today, Inc.
Share Price
$0.00001
Last synced: 2026-08-11
Market Cap
$3.02K
Change (1 day)
0.00%
Change (1 year)
-50.00%
Country
US
Trade SK3 Group, Inc. (SKTO)

Category

Healthcare
P/E ratio for SK3 Group, Inc. (SKTO)
P/E ratio as of 2026 TTM: 0
According to SK3 Group, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for SK3 Group, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.